Date published: 2026-3-3
Visit Santa Cruz Animal Health

1-800-457-3801

SCBT Portrait Logo
Seach Input
Contact Us
Sign In Account
Quick Order
Cart (0)
NF 449 (CAS 389142-38-5) - chemical structure image
Molecular structure of NF 449, CAS Number: 389142-38-5
NF 449 (CAS 389142-38-5) - chemical structure image
Molecular structure of NF 449, CAS Number: 389142-38-5
Molecular structure of NF 449, CAS Number: 389142-38-5

NF 449 (CAS 389142-38-5)

5.0(1)
Write a reviewAsk a question

See product citations (5)

Alternate Names:
4,4′,4′′,4′′′-[Carbonylbis(imino-5,1,3-be nzenetriyl-bis(carbonylimino))]tetrakis-1,3-benzen edisulfonic acid octasodium salt
Application:
NF 449 is a selective G-protein antagonist
CAS Number:
389142-38-5
Purity:
≥95%
Molecular Weight:
1505.09
Molecular Formula:
C41H24N6O29S8•8Na
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis

NF 449 is a selective Gsalpha-subunit G-protein antagonist which reduces the association rate of guanosine 5′-[gamma-thio]triphosphate ([35S]GTP[gammaS]) binding to Galpha s -s (Gsalpha-s) and inhibits the stimulation of adenylyl cyclase activity in S49 cyc- membranes. In addition, NF 449 interferes with binding between the Adenosine A1-R (A1-adenosine receptor) and its cognate G proteins (Gi/Go). Alternate studies suggest that NF449 inhibits a wide array of P2 receptors such as P2X3, P2Y1, and P2Y2, while showing the highest selectivity towards P2X1. Furthermore, NF449 can disrupt the coupling of beta-AR (beta-adrenergic receptors). NF449 octasodium salt is a chemical compound that has garnered considerable attention in scientific research. It serves as a powerful and selective antagonist of P2X1 and P2X3 receptors, which play roles in different physiological and pathological processes. Researchers extensively employ NF449 octasodium salt to investigate the involvement of P2X1 and P2X3 receptors in various physiological and pathological processes.


NF 449 (CAS 389142-38-5) References

  1. NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors.  |  Braun, K., et al. 2001. Naunyn Schmiedebergs Arch Pharmacol. 364: 285-90. PMID: 11521173
  2. Regulation of NF-kappaB activation by protein phosphatase 2B and NO, via protein kinase A activity, in human monocytes.  |  Bengoechea-Alonso, MT., et al. 2003. Nitric Oxide. 8: 65-74. PMID: 12586544
  3. Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist.  |  Kassack, MU., et al. 2004. Eur J Med Chem. 39: 345-57. PMID: 15072843
  4. Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways.  |  Peart, JN. and Gross, GJ. 2006. Am J Physiol Heart Circ Physiol. 291: H1746-53. PMID: 16731654
  5. Targeted disruption of the A2A adenosine receptor reduces in-vitro prostate contractility in mature mice.  |  Gray, KT., et al. 2008. Eur J Pharmacol. 592: 151-7. PMID: 18655781
  6. Hypoxia-induced mitogenic factor/FIZZ1 induces intracellular calcium release through the PLC-IP(3) pathway.  |  Fan, C., et al. 2009. Am J Physiol Lung Cell Mol Physiol. 297: L263-70. PMID: 19429774
  7. Functional evidence for the expression of P2X1, P2X4 and P2X7 receptors in human lung mast cells.  |  Wareham, K., et al. 2009. Br J Pharmacol. 157: 1215-24. PMID: 19552691
  8. The dual nature of extracellular ATP as a concentration-dependent platelet P2X1 agonist and antagonist.  |  Karunarathne, W., et al. 2009. Integr Biol (Camb). 1: 655-63. PMID: 20027374
  9. P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions.  |  Maloney, SF., et al. 2010. Integr Biol (Camb). 2: 183-92. PMID: 20473398
  10. Pharmacological characterization of the P2 receptors profile in the podocytes of the freshly isolated rat glomeruli.  |  Ilatovskaya, DV., et al. 2013. Am J Physiol Cell Physiol. 305: C1050-9. PMID: 24048730
  11. P2X7 receptors induce degranulation in human mast cells.  |  Wareham, KJ. and Seward, EP. 2016. Purinergic Signal. 12: 235-46. PMID: 26910735
  12. Multiple molecular pathways stimulating macroautophagy protect from alpha-synuclein-induced toxicity in human neurons.  |  Höllerhage, M., et al. 2019. Neuropharmacology. 149: 13-26. PMID: 30731136
  13. Two forms of G protein-coupled estrogen receptor 1 in the ricefield eel: Expression and functional characterization in relation to ovarian follicle development.  |  Meng, F., et al. 2021. Gen Comp Endocrinol. 304: 113720. PMID: 33508329
  14. Signaling Mechanism for Modulation by GLP-1 and Exendin-4 of GABA Receptors on Rat Retinal Ganglion Cells.  |  Zhang, T., et al. 2022. Neurosci Bull. 38: 622-636. PMID: 35278196
  15. Gsalpha-selective G protein antagonists.  |  Hohenegger, M., et al. 1998. Proc Natl Acad Sci U S A. 95: 346-51. PMID: 9419378

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

NF 449, 10 mg

sc-203159
10 mg
$314.00
1-800-457-3801
Visit Santa Cruz Animal Health|Visit San Juan Ranch
Santa Cruz Animal Health is a leading provider of animal health care products. ©2026 Santa Cruz Biotechnology Inc. All Rights Reserved.
Toll-Free: 1-800-457-3801 - Terms & Conditions | Privacy Policy | Legal
“Santa Cruz Animal Health”, “San Juan Ranch”, the San Juan Ranch logo, “UltraCruz”, “Supplement of Champions”, are registered trademarks of Santa Cruz Biotechnology, Inc. All other trademarks are the property of their respective owners.